Latest Insider Transactions at Cerus Corp (CERS)
This section provides a real-time view of insider transactions for Cerus Corp (CERS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CERUS CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CERUS CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2023
|
Daniel N Swisher Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+27.67%
|
$200,000
$5.0 P/Share
|
|
Jun 07
2023
|
Frank Witney Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.99%
|
$200,000
$5.0 P/Share
|
|
Jun 07
2023
|
Timothy L. Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+27.57%
|
$200,000
$5.0 P/Share
|
|
Jun 07
2023
|
Jami K Nachtsheim Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+27.33%
|
$200,000
$5.0 P/Share
|
|
Jun 07
2023
|
Gail Schulze Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.48%
|
$200,000
$5.0 P/Share
|
|
Jun 07
2023
|
Eric Bjerkholt |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.67%
|
$200,000
$5.0 P/Share
|
|
Jun 07
2023
|
Ann Lucena Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+38.17%
|
$200,000
$5.0 P/Share
|
|
May 26
2023
|
Daniel N Swisher Jr Director |
BUY
Open market or private purchase
|
Direct |
5,000
+4.04%
|
$5,000
$1.91 P/Share
|
|
May 24
2023
|
Gail Schulze Director |
BUY
Open market or private purchase
|
Direct |
9,850
+10.56%
|
$19,700
$2.03 P/Share
|
|
May 23
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
5,000
+5.74%
|
$10,000
$2.0 P/Share
|
|
Mar 13
2023
|
Carol Moore SVP Reg. & Quality |
SELL
Open market or private sale
|
Direct |
13,078
-1.57%
|
$26,156
$2.8 P/Share
|
|
Mar 13
2023
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,356
-1.92%
|
$50,712
$2.8 P/Share
|
|
Mar 13
2023
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,468
-2.2%
|
$30,936
$2.8 P/Share
|
|
Mar 13
2023
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
60,480
-1.14%
|
$120,960
$2.8 P/Share
|
|
Mar 13
2023
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
17,163
-1.97%
|
$34,326
$2.8 P/Share
|
|
Mar 13
2023
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,353
-2.36%
|
$50,706
$2.79 P/Share
|
|
Mar 13
2023
|
Laurence M Corash Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,342
-0.34%
|
$30,684
$2.8 P/Share
|
|
Mar 12
2023
|
Carol Moore SVP Reg. & Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
35,127
+4.01%
|
-
|
|
Mar 12
2023
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,200
+4.95%
|
-
|
|
Mar 12
2023
|
Chrystal Menard Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,127
+5.4%
|
-
|
|
Mar 12
2023
|
William Mariner Greenman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
172,192
+3.12%
|
-
|
|
Mar 12
2023
|
Kevin Dennis Green Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,127
+4.91%
|
-
|
|
Mar 12
2023
|
Richard J Benjamin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,127
+5.28%
|
-
|
|
Mar 12
2023
|
Laurence M Corash Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,127
+0.88%
|
-
|
|
Mar 01
2023
|
Chrystal Menard Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+33.0%
|
-
|
|
Mar 01
2023
|
Carol Moore SVP Reg. & Quality |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+21.83%
|
-
|
|
Mar 01
2023
|
Laurence M Corash Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+4.69%
|
-
|
|
Mar 01
2023
|
Kevin Dennis Green Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,000
+31.2%
|
-
|
|
Mar 01
2023
|
William Mariner Greenman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
575,000
+18.42%
|
-
|
|
Mar 01
2023
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,000
+28.1%
|
-
|
|
Mar 01
2023
|
Richard J Benjamin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+32.48%
|
-
|
|
Nov 10
2022
|
Daniel N Swisher Jr Director |
SELL
Open market or private sale
|
Direct |
12,500
-9.9%
|
$37,500
$3.91 P/Share
|
|
Nov 10
2022
|
Daniel N Swisher Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+9.01%
|
$37,500
$3.19 P/Share
|
|
Aug 15
2022
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-5.72%
|
$50,000
$5.18 P/Share
|
|
Aug 09
2022
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-5.47%
|
$50,000
$5.12 P/Share
|
|
Jul 01
2022
|
Hua Shan Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,886
+50.0%
|
-
|
|
Jun 01
2022
|
Eric Bjerkholt |
BUY
Grant, award, or other acquisition
|
Direct |
20,454
+20.96%
|
-
|
|
Jun 01
2022
|
Timothy L. Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,454
+23.92%
|
-
|
|
Jun 01
2022
|
Jami K Nachtsheim Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,454
+23.56%
|
-
|
|
Jun 01
2022
|
Gail Schulze Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,454
+29.63%
|
-
|
|
Jun 01
2022
|
Daniel N Swisher Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,454
+15.23%
|
-
|
|
Jun 01
2022
|
Frank Witney Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,454
+14.56%
|
-
|
|
May 10
2022
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
57,335
-20.45%
|
$229,340
$4.98 P/Share
|
|
Mar 14
2022
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
30,307
-5.93%
|
$151,535
$5.04 P/Share
|
|
Mar 14
2022
|
Carol Moore SVP Reg. & Quality |
SELL
Open market or private sale
|
Direct |
28,513
-3.44%
|
$142,565
$5.04 P/Share
|
|
Mar 14
2022
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
30,307
-5.67%
|
$151,535
$5.04 P/Share
|
|
Mar 14
2022
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,102
-3.9%
|
$160,510
$5.04 P/Share
|
|
Mar 14
2022
|
Laurence M Corash Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
30,307
-0.48%
|
$151,535
$5.04 P/Share
|
|
Mar 14
2022
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
41,734
-3.85%
|
$208,670
$5.04 P/Share
|
|
Mar 14
2022
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
165,021
-2.78%
|
$825,105
$5.04 P/Share
|